Interestingly, the CypA inhibitors C9 and CsA, either alone or in combination with afatinib, were more effective against EGFR-mutant NSCLC CSCs than EGFR-wild-type NSCLC CSCs. Here, EGFR is linked to non-small cell lung carcinoma.